These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8108211)

  • 1. Immunogenicity of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer membrane protein complex conjugate vaccine in infants and children with sickle cell disease.
    Newcomer W; Santosham M; Bengston S; Panny S; Dover G
    Pediatr Infect Dis J; 1993 Dec; 12(12):1026-7. PubMed ID: 8108211
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine.
    Weinberg GA; Einhorn MS; Lenoir AA; Granoff PD; Granoff DM
    J Pediatr; 1987 Jul; 111(1):22-7. PubMed ID: 3110388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-related immunogenicity of Haemophilus influenzae type b capsular polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine.
    Wong VK; Quagliata R; Adler R; Kim KS
    Am J Dis Child; 1991 Jul; 145(7):742-5. PubMed ID: 2058604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemophilus influenzae type b vaccines: history, choice and comparisons.
    Decker MD; Edwards KM
    Pediatr Infect Dis J; 1998 Sep; 17(9 Suppl):S113-6. PubMed ID: 9781742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.
    Santosham M; Wolff M; Reid R; Hohenboken M; Bateman M; Goepp J; Cortese M; Sack D; Hill J; Newcomer W
    N Engl J Med; 1991 Jun; 324(25):1767-72. PubMed ID: 1903846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of Haemophilus influenzae type b-meningococcus group B outer membrane protein conjugate vaccine in children 2-60 months of age.
    Shehab ZM; Azimi P; Asmar BI; Dunphy MG; Ayoub EM; Dajani AS
    Scand J Infect Dis; 1991; 23(6):763-9. PubMed ID: 1815340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An enzyme-linked immunosorbent assay for quantitation of Haemophilus Influenzae type b polysaccharide-specific IgG1 and IgG2 in human and infant rhesus monkey sera.
    Dolan KT; Staub JM; Schofield TL; Ahonkhai VI; Ellis RW; Vella PP
    J Immunoassay; 1991; 12(4):543-64. PubMed ID: 1806588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population.
    Santosham M; Hill J; Wolff M; Reid R; Lukacs L; Ahonkhai V
    Pediatr Infect Dis J; 1991 Feb; 10(2):113-7. PubMed ID: 2062601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein.
    Ahonkhai VI; Lukacs LJ; Jonas LC; Calandra GB
    Vaccine; 1991 Jun; 9 Suppl():S38-41; discussion S42-3. PubMed ID: 1891956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Anderson EL; Osterholm MT; Holmes SJ; McHugh JE; Belshe RB; Medley F; Murphy TV
    J Pediatr; 1992 Aug; 121(2):187-94. PubMed ID: 1640282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children.
    Harrison LH; Tajkowski C; Croll J; Reid R; Hu D; Brenneman G; Weatherholtz RC; Santosham M
    J Pediatr; 1994 Oct; 125(4):571-6. PubMed ID: 7931875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).
    Gray BM
    Pediatrics; 1990 Apr; 85(4 Pt 2):694-7. PubMed ID: 2107521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
    Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
    J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in children with sickle cell disease.
    Rubin LG; Voulalas D; Carmody L
    Am J Dis Child; 1992 Mar; 146(3):340-2. PubMed ID: 1543182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a conjugated Haemophilus influenzae type B polysaccharide-Neisseria meningitidis outer membrane protein vaccine.
    Yeh SJ; Huang LM; Chen JM; Lee PI; Chang LY; Lin YJ; Chiu HH; Lee CY
    J Formos Med Assoc; 1997 Feb; 96(2):110-5. PubMed ID: 9071836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease.
    Walter EB; Moggio MV; Drucker RP; Wilfert CM
    Pediatr Infect Dis J; 1990 Sep; 9(9):632-5. PubMed ID: 2235187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines.
    Granoff DM; Rathore MH; Holmes SJ; Granoff PD; Lucas AH
    Vaccine; 1993; 11 Suppl 1():S46-51. PubMed ID: 8447176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection.
    Kaplan SL; Duckett T; Mahoney DH; Kennedy LL; Dukes CM; Schaffer DM; Mason EO
    J Pediatr; 1992 Mar; 120(3):367-70. PubMed ID: 1538281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.